Jack Anders Sells 1,864 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) CFO Jack Anders sold 1,864 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $72,770.56. Following the completion of the sale, the chief financial officer now directly owns 115,006 shares of the company's stock, valued at approximately $4,489,834.24. This trade represents a 1.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Revolution Medicines Trading Down 1.0 %

Shares of RVMD stock traded down $0.38 on Friday, reaching $38.11. The company's stock had a trading volume of 2,499,644 shares, compared to its average volume of 1,347,138. The stock's fifty day simple moving average is $40.55 and its 200-day simple moving average is $45.73. Revolution Medicines, Inc. has a 1 year low of $29.55 and a 1 year high of $62.40. The company has a market capitalization of $7.09 billion, a price-to-earnings ratio of -10.62 and a beta of 1.46.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.11). Equities research analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Remove Ads

Institutional Investors Weigh In On Revolution Medicines

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of Revolution Medicines by 14.7% in the 4th quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company's stock valued at $747,799,000 after purchasing an additional 2,185,082 shares during the last quarter. Farallon Capital Management LLC lifted its position in Revolution Medicines by 17.1% in the fourth quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock worth $579,498,000 after buying an additional 1,931,000 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Revolution Medicines by 54.5% during the fourth quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock worth $414,777,000 after buying an additional 3,346,755 shares during the period. Baker BROS. Advisors LP increased its position in Revolution Medicines by 4.9% during the fourth quarter. Baker BROS. Advisors LP now owns 7,936,972 shares of the company's stock valued at $347,163,000 after acquiring an additional 367,882 shares during the last quarter. Finally, Nextech Invest Ltd. increased its position in Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after acquiring an additional 1,304,347 shares during the last quarter. 94.34% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

RVMD has been the subject of several recent analyst reports. HC Wainwright upped their target price on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. UBS Group upped their price objective on Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Stifel Nicolaus decreased their target price on Revolution Medicines from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. Guggenheim upped their price target on Revolution Medicines from $82.00 to $87.00 and gave the stock a "buy" rating in a research note on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Revolution Medicines from $63.00 to $71.00 and gave the company an "overweight" rating in a report on Tuesday, December 3rd. Twelve investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $66.31.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.